December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.
August 2019 in “Placenta” This article reviews the use of spironolactone in dermatology for conditions like female acne, suggesting it may reduce antibiotic and isotretinoin use, and stresses its long-term safety.
4 citations
,
January 2018 in “Forensic Science International” This study reported that a newly developed UHPLC-MS/MS method detected illegal synthetic hair-growth compounds in 10% of 76 hair-growth products, highlighting the need for ongoing monitoring to protect public health.
September 2025 in “The Journal of Clinical Psychiatry” Current evidence reviewed in this study indicates that finasteride, a drug for hair loss, can cause depression and suicidality, with delayed recognition partly due to insufficient post-approval pharmacovigilance by manufacturers and regulators.